
|Videos|October 24, 2022
Study measures patient rankings of third-line OAB treatments
Author(s)Urology Times staff
“We wanted to help provide an understanding of what factors guide patient choice of third line therapy for overactive bladder,” says Anjali Kapur, MD.
Advertisement
In this video, Anjali Kapur, MD, discusses the background and notable findings of the recent Neurourology and Urodynamics paper, “An analysis of factors that influence patient preference of third-line therapy for overactive bladder.” Kapur is a urology resident at Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
5













